New Jersey Patent of the Month – May 2024

ElectroCore, Inc., a leading bioelectronic medicine company, has made significant strides in the field of medical innovation with its latest invention aimed at treating symptoms of central nervous system disorders. This groundbreaking method utilizes non-invasive vagus nerve stimulation to provide relief to patients suffering from conditions such as fibromyalgia, anxiety disorders, post-traumatic stress disorder (PTSD), and traumatic brain injury.

The method involves positioning a contact surface of a device on the anterior portion of the neck, applying electrical impulses transcutaneously to the vagus nerve according to a specific stimulation protocol. These impulses, administered multiple times a day over several days, effectively modify the vagus nerve to alleviate symptoms associated with the respective central nervous system disorder.

What makes this invention truly revolutionary is its non-invasive nature and precise stimulation protocol. Unlike traditional methods that may involve invasive procedures or medications with potential side effects, this approach offers a safer and more targeted solution. By harnessing the body’s natural pathways and utilizing advanced technology, ElectroCore has developed a method that not only addresses the symptoms but also promotes overall well-being.

The device itself comprises one or more electrodes coupled to an energy source, providing a user-friendly interface for patients. With electrodes attached to the neck, the device delivers electrical impulses with specific parameters tailored to each individual’s needs. The stimulation protocol, including the frequency and duration of impulses, ensures optimal efficacy while minimizing discomfort.

Moreover, this method holds promise for a wide range of central nervous system disorders, offering a versatile treatment option for patients with varying needs. Whether it’s managing chronic pain associated with fibromyalgia or alleviating the symptoms of anxiety and PTSD, this innovation opens new possibilities for improving quality of life.

The potential impact of this invention extends beyond symptom management. By targeting the underlying mechanisms of central nervous system disorders, such as the release of inhibitory neurotransmitters in the brain, ElectroCore’s method represents a significant advancement in the field of neurostimulation.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts